CA2935804A1 — Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
Assigned to Dana Farber Cancer Institute Inc · Expires 2015-07-23 · 11y expired
What this patent protects
The present invention relates to compositions and methods for identifying, assessing, preventing, and treating melanoma. A variety of PD-Ll isoform biomarkers are provided, wherein alterations in the copy number of one or more of the biomarkers and/or alterations in the amount, s…
USPTO Abstract
The present invention relates to compositions and methods for identifying, assessing, preventing, and treating melanoma. A variety of PD-Ll isoform biomarkers are provided, wherein alterations in the copy number of one or more of the biomarkers and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers is associated with melanoma status.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.